BioStock interviews Michael-Robin Witt, CEO Gabather.
Gabather raises 62 MSEK to finance their study with GT-002. The study will be a combined phase 1b/2a and conducted as an adaptive study instead of a conventional. CEO Michael-Robin Witt explains more about an adaptive study and its advantages. GT-002 is Gabathers main drug candidate and aims to treat CNS diseases as Schizofrenia.